Hallie Wimberly
Overview
Explore the profile of Hallie Wimberly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
972
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pelekanou V, Carvajal-Hausdorf D, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, et al.
Breast Cancer Res
. 2017 Sep;
19(1):109.
PMID: 28946899
No abstract available.
2.
Pelekanou V, Carvajal-Hausdorf D, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, et al.
Breast Cancer Res
. 2017 Aug;
19(1):91.
PMID: 28784153
Background: The effects of neoadjuvant chemotherapy on immune markers remain largely unknown. The specific aim of this study was to assess stromal tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1...
3.
Wimberly H, Brown J, Schalper K, Haack H, Silver M, Nixon C, et al.
Cancer Immunol Res
. 2014 Dec;
3(4):326-32.
PMID: 25527356
Programmed death 1 ligand 1 (PD-L1) is an immune regulatory molecule that limits antitumor immune activity. Targeting of PD-L1 and other immune checkpoint proteins has shown therapeutic activity in various...
4.
Brown J, Wimberly H, Lannin D, Nixon C, Rimm D, Bossuyt V
Clin Cancer Res
. 2014 Sep;
20(23):5995-6005.
PMID: 25255793
Purpose: Although tumor-infiltrating lymphocytes (TIL) have been associated with response to neoadjuvant therapy, measurement typically is subjective, semiquantitative, and unable to differentiate among subpopulations. Here, we describe a quantitative objective...
5.
Wimberly H, Han G, Pinnaduwage D, Murphy L, Yang X, Andrulis I, et al.
Breast Cancer Res Treat
. 2014 Jul;
146(3):657-67.
PMID: 25007965
Though the role of Estrogen Receptor (ER)α in breast cancer has been studied extensively, there is little consensus about the role of alternative ER isoform ERβ in breast cancer biology....
6.
Schalper K, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, et al.
Clin Cancer Res
. 2014 Mar;
20(10):2773-82.
PMID: 24647569
Purpose: Blockade of the PD-1/PD-L1 axis emerged as a promising new therapeutic option for cancer that has resulted in lasting responses in metastatic renal, lung carcinomas, and melanomas. Tumor PD-L1...
7.
Wimberly H, Shee C, Thornton P, Sivaramakrishnan P, Rosenberg S, Hastings P
Nat Commun
. 2013 Jul;
4:2115.
PMID: 23828459
Double-stranded DNA ends, often from replication, drive genomic instability, yet their origin in non-replicating cells is unknown. Here we show that transcriptional RNA/DNA hybrids (R-loops) generate DNA ends that underlie...
8.
Moore J, Wimberly H, Thornton P, Rosenberg S, Hastings P
Ann N Y Acad Sci
. 2012 Sep;
1267:103-9.
PMID: 22954223
Gross chromosomal rearrangements (GCRs), or changes in chromosome structure, play central roles in evolution and are central to cancer formation and progression. GCRs underlie copy number variation (CNV), and therefore...
9.
Welsh A, Harigopal M, Wimberly H, Prasad M, Rimm D
Appl Immunohistochem Mol Morphol
. 2012 Jul;
21(2):139-47.
PMID: 22820659
Studies comparing rabbit monoclonal SP1 antibody with 1D5 for estrogen receptor (ER) immunohistochemical testing show conflicting results. Here we use a standardized quantitative immunofluorescent (QIF) ER assay to determine the...
10.
Hanna J, Wimberly H, Kumar S, Slack F, Agarwal S, Rimm D
Biotechniques
. 2012 Apr;
52(4):235-45.
PMID: 22482439
MicroRNAs (miRNAs) have emerged as key regulators in the pathogenesis of cancers where they can act as either oncogenes or tumor suppressors. Most miRNA measurement methods require total RNA extracts...